Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol Getting Eagerly Awaited First-Line Opdivo Lung Data Earlier Than Expected

Executive Summary

Bristol-Myers Squibb Co. is moving up the timing on its eagerly awaited CheckMate-026 first-line lung cancer trial of Opdivo, with data now expected in the third quarter – earlier than prior guidance.

Advertisement

Related Content

Merck Oncology Strategy: With First-Line Lung Data, A New Day Dawns For Keytruda
Immuno-Oncology's Next Wave: Key Targets And Emerging Players
Merck Is Finding PD-L1 Testing Is Helping Keytruda
BMS: Sales For Opdivo Are Flying High

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC065071

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel